TC
BMRN icon

TFS Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

TFS Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,426
Closed -$402K – 47
2017
Q2 		$402K Hold
4,426
– – 0.16% 264
2017
Q1 		$389K Hold
4,426
– – 0.13% 299
2016
Q4 		$367K Buy
+4,426
New +$381K 0.1% 363
2013
Q4 		– Sell
-3,754
Closed -$271K – 1477
2013
Q3 		$271K Buy
+3,754
New +$249K 0.01% 1142

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TFS Capital's BMRN Position: Q3 2017 in Review

TFS Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 4,426 shares — an estimated $402K sold.

TFS Capital first reported a position in BMRN in Q3 2013 and held it in 4 quarters. The position peaked at $402K in Q2 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • TFS Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 4,426 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $402K.
  • TFS Capital first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 4 quarters.
  • TFS Capital's BioMarin Pharmaceuticals position peaked at $402K in Q2 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.